Benjamin M. Wu
Roche (United States) · 81 works · 1,787 citations · h-index 23
Top works
- Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
- Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody
- Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities
- Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
- Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab‐Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity
- A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
- Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
- Pharmacokinetics of the Antimalarial Drug, AQ-13, in Rats and Cynomolgus Macaques
- The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab
- Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors
- Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
- Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150
- Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow‐Up
- Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
- Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework
- A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
- Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis
- Time-dependent population PK models of single-agent atezolizumab in patients with cancer
- Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
- Development and application of an analytical method for the determination of squalene in formulations of anthrax vaccine adsorbed